Abstract
The human plasma contact system is an immune surveillance system activated by the negatively charged surfaces of bacteria and fungi and includes the kallikrein-kinin, the coagulation, and the fibrinolytic systems. Previous work shows that the contact system also activates complement, and that plasma enzymes like kallikrein, plasmin, thrombin, and FXII are involved in the activation process. Here, we show for the first time that kallikrein cleaves the central complement component C3 directly to yield active components C3b and C3a. The cleavage site within C3 is identical to that recognized by the C3 convertase. Also, kallikrein-generated C3b forms C3 convertases, which trigger the C3 amplification loop. Since kallikrein also cleaves factor B to yield Bb and Ba, kallikrein alone can trigger complement activation. Kallikrein-generated C3 convertases are inhibited by factor H; thus, the kallikrein activation pathway merges with the amplification loop of the alternative pathway. Taken together, these data suggest that activation of the contact system locally enhances complement activation on cell surfaces. The human pathogenic microbe Candida albicans activates the contact system in normal human serum. However, C. albicans immediately recruits factor H to the surface, thereby evading the alternative and likely kallikrein-mediated complement pathways.
Journal Section:
Editor's choice
References
1.
Nickel KF, Renné T: Crosstalk of the plasma contact system with bacteria. Thromb Res 2012;130:S78-S83.
2.
Maas C, Oschatz C, Renné T: The plasma contact system 2.0. Semin Thromb Hemost 2011;37:375-381.
3.
Zerleder S: C1-inhibitor: more than a serine protease inhibitor. Semin Thromb Hemost 2011;37:362-374.
4.
Derkx FH, Bouma BN, Schalekamp MP, Schalekamp MA: An intrinsic factor XII- prekallikrein-dependent pathway activates the human plasma renin-angiotensin system. Nature 1979;280:315-316.
5.
Ekdahl KN, Teramura Y, Hamad OA, Asif S, Duehrkop C, Fromell K, Gustafson E, Hong J, Kozarcanin H, Magnusson PU, Huber-Lang M, Garred P, Nilsson B: Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunol Rev 2016;274:245-269.
6.
Lachmann PJ: The amplification loop of the complement pathways. Adv Immunol 2009;104:115-149.
7.
Ghebrehiwet B: The complement system: an evolution in progress. F1000Research 2016;5:2840.
8.
Zipfel PF, Skerka C: Complement regulators and inhibitory proteins. Nat Rev Immunol 2009;9:729-740.
9.
Wiegner R, Chakraborty S, Huber-Lang M: Complement-coagulation crosstalk on cellular and artificial surfaces. Immunobiology 2016;221:1073-1079.
10.
Ricklin D, Hajishengallis G, Yang K, Lambris JD: Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785-797.
11.
Amara U, Flierl MA, Rittirsch D: Molecular intercommunication between the complement and coagulation systems. J Immunol 2010;185:5628-5636.
12.
Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA: Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006;12:682-687.
13.
Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP: Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983;71:1450-1456.
14.
DiScipio RG: The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 1982;45:587-595.
15.
Hiemstra PS, Daha MR, Bouma BN: Activation of factor B of the complement system by kallikrein and its light chain. Thromb Res 1985;38:491-503.
16.
Yaseen S, Demopulos G, Dudler T, Yabuki M, Wood CL, Cummings WJ, Tjoelker LW, Fujita T, Sacks S, Garred P, Andrew P, Sim RB, Lachmann PJ, Wallis R, Lynch N, Schwaeble WJ: Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2. FASEB J 2017;31:2210-2219.
17.
Krarup A, Wallis R, Presanis JS, Gál P, Sim RB: Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One 2007;2:e623.
18.
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317.
19.
Brown GD, Denning DW, Levitz SM: Tackling human fungal infections. Science 2012;336:647.
20.
Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C: In vivo roles of factor XII. Blood 2012;120:4296-4303.
21.
Luo S, Skerka C, Kurzai O, Zipfel PF: Complement and innate immune evasion strategies of the human pathogenic fungus Candida albicans. Mol Immunol 2013;56:161-169.
22.
Gillum AM, Tsay EY, Kirsch DR: Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 1984;198:179-182.
23.
Eberhardt HU, Buhlmann D, Hortschansky P, Chen Q, Böhm S, Kemper MJ, Wallich, R, Hartmann A, Hallström T, Zipfel PF, Skerka C: Human factor H-related protein 2 (CFHR2) regulates complement activation. PLoS One 2013;8:e78617.1.23.
24.
Janssen BJC, Christodoulidou A, McCarthy A, Lambris JD, Gros P: Structure of C3b reveals conformational changes that underlie complement activity. Nature 2006;444:213-216.
25.
Sonesson A, Ringstad L, Nordahl EA, Malmsten M, Mörgelin M, Schmidtchen A: Antifungal activity of C3a and C3a-derived peptides against Candida. Biochim Biophys Acta 2007;1768:346-353.
26.
Morrison DC, Cochrane CG: Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 1974;140:797-811.
27.
Kalter ES, van Dijk WC, Timmerman A, Verhoef J, Bouma BN: Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis 1983;148:682-691.
28.
Chung DW, Fujikawa K, McMullen BA, Davie EW: Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 1986;25:2410-2417.
29.
Wuepper KD, Cochrane CG: Effect of plasma kallikrein on coagulation in vitro. Proc Soc Exp Biol Med 1972;141:271-276.
30.
Hong SL: Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb Res 1980;18:787-795.
31.
Woodruff RS, Sullenger B, Becker RC: The many faces of the contact pathway and their role in thrombosis. J Thromb Thrombolysis 2011;32:9-20.
32.
Ghebrehiwet B, Silverberg M, Kaplan AP: Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 1981;153:665-676.
33.
Tosi M: Molecular genetics of C1 inhibitor. Immunobiology 1998;199:358-365.
34.
Mayilyan KR: Complement genetics, deficiencies, and disease associations. Prot Cell 2012;3487-3496.
35.
Schmaier AH: The elusive physiologic role of Factor XII. J Clin Invest 2008;118:3006-3009.
36.
Karkowska-Kuleta J, Kozik A, Rapala-Kozik M: Binding and activation of the human plasma kinin-forming system on the cell walls of Candida albicans and Candida tropicalis. Biol Chem 2010;391:97-103.
37.
Kaminishi H, Tanaka M, Cho T, Maeda H, Hagihara Y: Activation of the plasma kallikrein-kinin system by Candida albicans proteinase. Infect Immun 1990;58:2139-2143.
38.
Frick IM, Björck L, Herwald H: The dual role of the contact system in bacterial infectious disease. Thromb Haemost 2007;98:497-502.
39.
Foley JH, Walton BL, Aleman MM, O'Bryne AM, Lei V, Harrasser M, Foley, KA, Wolberg AS, Conway EM: Complement activation in arterial and venous thrombosis is mediated by plasmin. EBioMedicine 2016;5:175-182.
40.
Ben Nasr AB, Herwald H, Müller-Esterl W, Björck L: Human kininogens interact with M protein, a bacterial surface protein and virulence determinant. Biochem J 1995;305:173-180.
41.
Imamura T, Potempa J, Travis J: Activation of the kallikrein-kinin system and release of new kinins through alternative cleavage of kininogens by microbial and human cell proteinases. Biol Chem 2004;385:989-996.
© 2017 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.
